The counter had a total traded volume of 12:40PM shares so far with a turnover of Rs 17.01 crore on BSE. The stock traded at a price-to-earnings multiple of 10.97 and a price-to-book ratio of 1.44.
A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
Promotor/FII Holding
Promoters held 51.94 per cent stake in the company as of 31-Mar-2021, while FIIs and domestic institutional investors ownership stood at 26.62 per cent and 10.99 per cent, respectively.
Key Financials
The firm reported consolidated net sales of Rs 6498.31 crore for the quarter ended 31-Dec-2020, down 0.59 per cent from the previous quarter’s Rs 6537.19 crore and down 9.66 per cent from the year-ago quarter’s Rs 5925.93 crore.
Its profit for the latest quarter stood at Rs 2946.46 crore, up 317.67 per cent from the same quarter a year ago.
